CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, California.
加利福尼亞州聖卡洛斯，2024年12月17日（環球新聞通訊社）—— CARGO Therapeutics, Inc.（納斯達克：CRGX）是一家臨床階段的生物技術公司，致力於推進下一代可能治癒癌症患者的電芯療法，今天宣佈該公司將參加於2025年1月13日至16日在加利福尼亞州舊金山舉行的第43屆J.P.摩根醫療保健會議。
Gina Chapman, President and Chief Executive Officer, is scheduled to present on Monday, January 13, at 10:30 a.m. PT.
總裁兼首席執行官吉娜·查普曼定於1月13日星期一上午10:30（太平洋時間）進行演講。
Interested parties can access the live webcast for the presentation in the Investors section of CARGO's website under News & Events. A replay of the webcast will be available after the conclusion of the live presentation for approximately 30 days.
感興趣的各方可以在CARGO網站的投資者部分下的資訊與活動中訪問演講的直播 webcast。直播演講結束後，webcast的重播將在大約30天內提供。
About CARGO Therapeutics
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company positioned to advance next- generation, potentially curative cell therapies for cancer patients. CARGO's programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of effect, safety concerns and unreliable supply. CARGO is currently evaluating firicabtagene autoleucel (firi-cel), an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, in a potentially pivotal Phase 2 clinical study in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. CARGO has developed proprietary cell engineering platform technologies which it leverages to develop a pipeline of programs that incorporate multiple transgene therapeutic "cargo" designed to enhance CAR T-cell persistence and trafficking to tumor lesions, as well as to help safeguard against tumor resistance and T-cell exhaustion. This includes the CRG-023 program, which incorporates a novel tri-specific CAR T with CD2 co-stimulation that is designed to address several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy across a broad range of B-cell malignancies with the goal of providing more patients with a durable complete response. CARGO's leadership and team have significant experience in developing, engineering, manufacturing, and commercializing oncology and cell therapy products. For more information, please visit the CARGO Therapeutics website at .
Follow us on LinkedIn: CARGO Therapeutics
Follow us on X (Twitter): @CARGOTx
關於CARGO Therapeutics
CARGO Therapeutics, Inc.是一家臨床階段的生物技術公司，致力於推進下一代可能治癒癌症患者的電芯療法。CARGO的項目、平台技術和製造策略旨在直接解決已批准的電芯療法的侷限性，包括有限的效果持續性、安全性問題和不可靠的供應。CARGO當前正在評估firicabtagene autoleucel（firi-cel），這是一種自體CD22嵌合抗原受體（CAR）t細胞療法候選藥物，針對大b細胞淋巴瘤（LBCL）患者，這些患者的疾病在對CD19 CAR t細胞療法時出現復發或難治（R/R）。CARGO開發了專有的電芯工程平台技術，以開發一系列項目，這些項目結合了多種轉基因治療「貨物」，旨在增強CAR t細胞的持久性和腫瘤病竈的轉移，並幫助防止腫瘤耐藥性和t細胞疲勞。這包括CRG-023項目，它結合了一種新型的三特異性CAR t與CD2共刺激，旨在解決已知復發的幾種原因，從而在廣泛的b細胞惡性腫瘤中提供潛在的最佳CAR t細胞療法，目標是爲更多患者提供持久的完全緩解。CARGO的領導團隊在開發、工程、製造和商業化腫瘤學和電芯治療產品方面擁有豐富的經驗。如需更多信息，請訪問CARGO Therapeutics網站。
關注我們的領英：CARGO Therapeutics
關注我們的X（推特）：@CARGOTx
Contacts
Media Contact:
Kimberly Muscara
kimberly@redhousecomms.com
聯繫人
媒體聯繫人：
金伯利·穆斯卡拉
kimberly@redhousecomms.com
Investor Contact:
Jessica Serra
jserra@cargo-tx.com
Laurence Watts
laurence@newstreetir.com
投資者聯繫人：
傑西卡·塞拉
jserra@cargo-tx.com
勞倫斯·瓦茨
laurence@newstreetir.com
譯文內容由第三人軟體翻譯。
